quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 13, 2025

Bitcoin 2030 Price Prediction: Will BTC Hit $500K or $1M?

View original at finance.yahoo.com
Bitcoin 2030 Price Prediction: Will BTC Hit $500K or $1M? Travis Wolfe / Shutterstock.com Quick Read Bitcoin trades around $90K after hitting $126K in October, marking a 26.3% correction from the peak…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Hundreds of publicly traded companies now hold Bitcoin following MicroStrategy's accumulation model

    80% confidence
  • Bitcoin could reach $500K to $1M by 2030 depending on institutional demand, supply compression, and adoption patterns

    80% confidence
  • Banks now use Bitcoin as collateral in lending markets

    80% confidence
  • Bullish case projects Bitcoin at $750K-$1M by 2030 if ETF assets approach $2 trillion and sovereign reserves expand

    80% confidence
  • Institutions now treat Bitcoin as a modern counterpart to gold for navigating unstable monetary conditions

    80% confidence
  • At $500K, Bitcoin's market cap would reach approximately $10 trillion, roughly 2% of global wealth and still below gold

    80% confidence
  • Global ETF demand could exceed $500-$800 billion by 2030

    80% confidence
  • Bearish case projects Bitcoin at $120K-$220K if structural demand weakens and ETF inflows flatten

    80% confidence
  • Price acceleration typically peaks 12-24 months after a halving event

    80% confidence
  • Base case projects Bitcoin at $350K-$500K with ETF assets moving toward $500-$800 billion range

    80% confidence

Data points we hold from this source

Bitcoin · daily issuance225 BTC
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com